Ablative chemoembolization (ACE) doubles response rate and progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC) compared with conventional transarterial chemoembolization (cTACE), a study by the Chinese University of Hong Kong (CUHK) has shown.
New guidelines published by the Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) aim to improve care for Asian patients on antithrombotic therapy who require emergency or elective endoscopy.
The addition of the multikinase inhibitor sorafenib to FOLFOX* or transarterial chemoembolization (TACE) demonstrated favourable clinical efficacy and improved survival outcomes in hepatocellular carcinoma (HCC), according to several studies presented at the ASCO Gastrointestinal Cancers Symposium 2018 (ASCO GI 2018).
Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.
Pembrolizumab demonstrated promising results in several outcomes among patients with advanced hepatocellular carcinoma (HCC) whose disease progressed on or who were unable to tolerate treatment with sorafenib, findings from the KEYNOTE-224* trial show.
High-risk patients may benefit from a protective effect of statins against hepatocellular carcinoma, a recent study suggests. This effect appears to be greater in patients with diabetes mellitus or liver cirrhosis.